New hope for kids with liver cancer: tailored chemotherapy trial launches

NCT ID NCT07300449

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing different chemotherapy plans for children with hepatoblastoma, a rare liver cancer. The goal is to find the best treatment for each risk group to improve survival and reduce side effects. The trial will enroll 100 children and teens across 15 hospitals in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (cisplatin, doxorubicin, ifosfamide, carboplatin, etoposide)
What this could lead to: If successful, this trial could identify safer and more effective chemotherapy combinations for children with hepatoblastoma, potentially improving survival rates for high-risk cases.
What could go wrong: This is a phase 2 trial with a relatively small number of participants, so results may not apply to all patients. Chemotherapy can cause significant side effects, and the intensified regimens may increase toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOBLASTOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.